Cover Image
市場調查報告書

EpiCast 到Report:肺動脈高血壓 - 2024年為止的流行病學預測

EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 351349
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast 到Report:肺動脈高血壓 - 2024年為止的流行病學預測 EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
出版日期: 2016年01月01日 內容資訊: 英文 72 Pages
簡介

在全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本),肺動脈高血壓和確診的患者數,預計從2014年的9,926人增加到2024年的10,285人。

本報告提供全球主要7個國家的肺動脈高血壓調查分析,疾病的背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 肺動脈高血壓的流行病學預測
    • 登記資料
    • 估價過低的調整
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER114-15

Pulmonary Arterial Hypertension (PAH) is a rare and severe condition characterized by vascular proliferation and remodeling of the small pulmonary arteries. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure. The disease typically results in right-sided heart failure and premature death. PAH can be idiopathic, heritable, or associated with different conditions such as connective tissue disease (CTD), congenital heart disease (CHD), human immunodeficiency virus (HIV) infection, and exposure to toxins or drugs. PAH occurs twice as frequently in women as in men.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of PAH in the 7MM, from 1,769 diagnosed incident cases in 2014 to 1,838 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 0.39% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of PAH in the 7MM, with 677 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of PAH, with 74 diagnosed incident cases. Similarly, the diagnosed prevalent cases of PAH in the 7MM are expected to increase from 9,926 diagnosed prevalent cases in 2014 to 10,285 diagnosed prevalent cases in 2024, with an AGR of 0.36% during the forecast period. In 2024, the US will have the highest number of diagnosed prevalent cases of PAH in the 7MM, with 4,325 diagnosed prevalent cases, whereas the UK will have the lowest number of diagnosed prevalent cases of PAH, with 443 diagnosed prevalent cases.

GlobalData's epidemiological forecast for the diagnosed incident and the diagnosed prevalent cases of PAH in the 7MM is supported by age- and sex-specific data. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed incident cases and diagnosed prevalent cases of PAH across the markets. Additionally, GlobalData epidemiologists provided the diagnosed prevalent cases of PAH in each of the 7MM, segmented by the NYHA functional class I-IV, which is an important factor for predicting the prognosis, as well as the need for various clinical and treatment modalities specific to the functional classes, for PAH. GlobalData epidemiologists also provide an additional forecast for the diagnosed incident and diagnosed prevalent cases of PAH, adjusted for the underestimation of registry based forecast. These two different types of forecast strengthen the analysis, and present a comparative assessment of the extent of underestimation when using registry based data, which can be evaluated to provide better insights on the burden of the condition.

Scope

  • The Pulmonary Arterial Hypertension (PAH) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases and diagnosed prevalent cases of PAH, segmented by sex, and age (in 10-year increments beginning at 0 years and ending at =85 years in these markets.
  • The PAH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The PAH EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global PAH market.
  • Quantify patient populations in the global PAH market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for PAH therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence and Prevalence
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for PAH (2014-2024)
    • 3.5.1. Epidemiological Forecast for PAH - Based on Registry Data
    • 3.5.2. Epidemiological Forecast for PAH - Adjusted for Underestimation
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: WHO Guidelines, Modified New York Heart Association Functional Classes I-IV
  • Table 2: Risk Factors and Comorbidities for PAH
  • Table 3: 7MM, Global Trends for the Diagnosed Incidence of PAH
  • Table 4: 7MM, Global Trends for the Diagnosed Prevalence of PAH
  • Table 5: 7MM Sources of Epidemiological Data Used for the Forecast for PAH Diagnosed Incident Cases (Based on Registry Data)
  • Table 6: 7MM Sources of Epidemiological Data Used for the Forecast for PAH Diagnosed Prevalent Cases (Based on Registry Data)
  • Table 7: 7MM Sources of Epidemiological Data Used for the Classification of Diagnosed Prevalent Cases* According to the NYHA Functional Classes I-IV
  • Table 8: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data)
  • Table 9: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N (Row %), 2014 (Based on Registry Data)
  • Table 10: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N (Row %), 2014 (Based on Registry Data)
  • Table 11: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data)
  • Table 12: 7MM Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N (Row %), 2014 (Based on Registry Data)
  • Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N (Row %), 2014 (Based on Registry Data)
  • Table 14: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation)
  • Table 15: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N (Row %), 2014 (Adjusted for Underestimation)
  • Table 16: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N (Row %), 2014 (Adjusted for Underestimation)
  • Table 17: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation)
  • Table 18: 7MM, Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N (Row %), 2014 (Adjusted for Underestimation)
  • Table 19: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N (Row %), 2014 (Adjusted for Underestimation)

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data)
  • Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N, 2014 (Based on Registry Data)
  • Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N, 2014 (Based on Registry Data)
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of PAH (Cases per 100,000 Population), All Ages, by Sex, 2014 (Based on Registry Data)
  • Figure 5: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Based on Registry Data)
  • Figure 6: 7MM Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N, 2014 (Based on Registry Data)
  • Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N, 2014 (Based on Registry Data)
  • Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of PAH (%), All Ages, by Sex, 2014 (Based on Registry Data)
  • Figure 9: 7MM, Diagnosed Prevalent Cases of PAH Categorized into NYHA Functional Classes (N), All Ages, 2014 (Based on Registry Data)
  • Figure 10: 7MM, Diagnosed Incident Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation)
  • Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of PAH, Both Sexes, N, 2014 (Adjusted for Underestimation)
  • Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of PAH, All Ages, N, 2014 (Adjusted for Underestimation)
  • Figure 13: 7MM, Diagnosed Prevalent Cases of PAH, Both Sexes, All Ages, N, 2014-2024 (Adjusted for Underestimation)
  • Figure 14: 7MM, Age-Specific Diagnosed Prevalent Cases of PAH, Both Sexes, N, 2014 (Adjusted for Underestimation)
  • Figure 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of PAH, All Ages, N, 2014 (Adjusted for Underestimation)
  • Figure 16: 7MM, Diagnosed Prevalent Cases of PAH Categorized into NYHA Functional Classes (N), All Ages, 2014 (Adjusted for Underestimation)
Back to Top